Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Elizabeth Smyth MD
Elizabeth Smyth MD Advisory Board
Guru Sonpavde MD
Guru P. Sonpavde MD Advisory Board
Benjamin Anderson MD, FACS
Benjamin O. Anderson MD, FACS Advisory Board
See All Experts
featured
Published in Oncology

Journal Scan / Research · September 25, 2024

Gilteritinib vs Salvage Chemotherapy for Relapsed/Refractory FLT3-Mutated AML

Leukemia

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Rodrigo Fonseca MD

Leukemia
Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia
Leukemia 2024 Sep 05;[EPub Ahead of Print], J Wang, B Jiang, J Li, L Liu, X Du, H Jiang, J Hu, M Yuan, T Sakatani, T Kadokura, M Takeuchi, M Kosako, X Ma, L Girshova, J Tan, S Bondarenko, LWL Lee, A Khuhapinant, E Martynova, N Hasabou

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated